Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Aprea Therapeutics, Inc. (APRE) reported a Q3 loss of $0.64 per share, which was better than the Zacks Consensus Estimate of a $0.75 loss. This is an improvement from the $0.86 loss per share reported a year ago.
November 07, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aprea Therapeutics reported a Q3 loss of $0.64 per share, beating the Zacks Consensus Estimate of a $0.75 loss. This marks an improvement from the previous year's $0.86 loss per share.
Aprea Therapeutics' Q3 loss was smaller than expected, which is a positive indicator for investors. The improvement from last year's loss suggests potential progress in the company's financial health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100